1. Home
  2. AFJK vs BLUE Comparison

AFJK vs BLUE Comparison

Compare AFJK & BLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AFJK
  • BLUE
  • Stock Information
  • Founded
  • AFJK 2023
  • BLUE 1992
  • Country
  • AFJK United States
  • BLUE United States
  • Employees
  • AFJK N/A
  • BLUE N/A
  • Industry
  • AFJK
  • BLUE Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • AFJK
  • BLUE Health Care
  • Exchange
  • AFJK NYSE
  • BLUE Nasdaq
  • Market Cap
  • AFJK 95.5M
  • BLUE 78.7M
  • IPO Year
  • AFJK 2023
  • BLUE 2013
  • Fundamental
  • Price
  • AFJK $10.60
  • BLUE $0.38
  • Analyst Decision
  • AFJK
  • BLUE Hold
  • Analyst Count
  • AFJK 0
  • BLUE 11
  • Target Price
  • AFJK N/A
  • BLUE $4.63
  • AVG Volume (30 Days)
  • AFJK 5.9K
  • BLUE 5.0M
  • Earning Date
  • AFJK 01-01-0001
  • BLUE 11-14-2024
  • Dividend Yield
  • AFJK N/A
  • BLUE N/A
  • EPS Growth
  • AFJK N/A
  • BLUE N/A
  • EPS
  • AFJK 0.27
  • BLUE N/A
  • Revenue
  • AFJK N/A
  • BLUE $53,120,000.00
  • Revenue This Year
  • AFJK N/A
  • BLUE $199.14
  • Revenue Next Year
  • AFJK N/A
  • BLUE $186.62
  • P/E Ratio
  • AFJK $40.08
  • BLUE N/A
  • Revenue Growth
  • AFJK N/A
  • BLUE 144.50
  • 52 Week Low
  • AFJK $10.15
  • BLUE $0.34
  • 52 Week High
  • AFJK $10.65
  • BLUE $5.53
  • Technical
  • Relative Strength Index (RSI)
  • AFJK N/A
  • BLUE 30.06
  • Support Level
  • AFJK N/A
  • BLUE $0.34
  • Resistance Level
  • AFJK N/A
  • BLUE $0.53
  • Average True Range (ATR)
  • AFJK 0.00
  • BLUE 0.03
  • MACD
  • AFJK 0.00
  • BLUE -0.01
  • Stochastic Oscillator
  • AFJK 0.00
  • BLUE 21.35

About AFJK AIMEI HEALTH TECHNOLOGY CO LTD

Aimei Health Technology Co Ltd is a blank check company.

About BLUE bluebird bio Inc.

bluebird bio Inc is a biotechnology company engaged in researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its proprietary lentiviral vector (LVV) gene addition platform. The Company operates in a single segment, focusing on researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases.

Share on Social Networks: